Literature DB >> 10611470

Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells.

K Bokvist1, M Hoy, K Buschard, J J Holst, M K Thomsen, J Gromada.   

Abstract

The effects of the two prandial glucose regulators, repaglinide and nateglinide, on ATP-sensitive K(+) (K(ATP)) channel activity, membrane potential and exocytosis in single rat pancreatic A-cells were investigated using the patch-clamp technique. K(ATP) channel activity was reversibly blocked by repaglinide (K(d)=22 nM) and nateglinide (K(d)=410 nM) and this was associated with membrane depolarisation and initiation of electrical activity. The effect of repaglinide and nateglinide on stimulation of glucagon secretion by direct interference with the exocytotic machinery was investigated by the use of capacitance measurements. Nateglinide, but not repaglinide, at concentrations similar to those required to block K(ATP) channels potentiated Ca(2+)-evoked exocytosis 3-fold. In alphaTC1-9 glucagonoma cells addition of nateglinide, but not repaglinide, was associated with stimulation of glucagon secretion. These results indicate that the fast-acting insulin secretagogue nateglinide is glucagonotropic primarily by stimulating Ca(2+)-dependent exocytosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611470     DOI: 10.1016/s0014-2999(99)00754-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Authors:  C R Culy; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Acute and long-term effects of nateglinide on insulin secretory pathways.

Authors:  Andrew J Ball; Peter R Flatt; Neville H McClenaghan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

3.  Repaglinide, but not nateglinide administered supraspinally and spinally exerts an anti-diabetic action in d-glucose fed and streptozotocin-treated mouse models.

Authors:  Yun-Beom Sim; Soo-Hyun Park; Yu-Jung Kang; Sung-Su Kim; Chea-Ha Kim; Su-Jin Kim; Su-Min Lim; Jun-Sub Jung; Ohk-Hyun Ryu; Moon-Gi Choi; Hong-Won Suh
Journal:  Korean J Physiol Pharmacol       Date:  2013-12-16       Impact factor: 2.016

4.  Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Authors:  Yuichi Terawaki; Chikayo Iwaya; Takashi Nomiyama; Dai Shimono; Tsuyoshi Horikawa; Yuki Fujimura-Tanaka; Toru Shigeoka; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase; Daiji Kawanami
Journal:  Diabetol Int       Date:  2020-02-14

Review 5.  A review of nateglinide in the management of patients with type 2 diabetes.

Authors:  Nicholas Tentolouris; Christina Voulgari; Nicholas Katsilambros
Journal:  Vasc Health Risk Manag       Date:  2007

6.  Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.

Authors:  Masumi Tanimoto; Akio Kanazawa; Takahisa Hirose; Tomoaki Yoshihara; Saeko Kobayashi-Kimura; Risa Nakanishi; Yuka Tosaka; Ruri Sasaki-Omote; Kyoko Kudo-Fujimaki; Koji Komiya; Fuki Ikeda; Yuki Someya; Tomoya Mita; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2015-03-15       Impact factor: 4.232

7.  Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.

Authors:  Ryuzo Kawamori; Kohei Kaku; Toshiaki Hanafusa; Katsuhisa Ioriya; Shigeru Kageyama; Nigishi Hotta
Journal:  J Diabetes Investig       Date:  2015-07-19       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.